[stock_market_widget type=”card” template=”basic2″ assets=”GOSS” realtime=”true” api=”yahoo-finance”]
Gossamer Bio, Inc. (NASDAQ: GOSS) is a San Diego-based biopharmaceutical company focused on developing treatments for pulmonary arterial hypertension (PAH), a rare and serious condition affecting the lungs and heart. The company confirmed today the final tender results of a debt exchange offer that had been in the works for several weeks. The transaction reshapes the company’s balance sheet in ways that matter to anyone who owns the stock or is watching the company’s pipeline.
The starting point is a set of existing notes. Gossamer had $200 million in 5.00% Convertible Senior Notes due in 2027 sitting on its books. Unsecured debt like this ranks lower in the repayment hierarchy if a company ever hits serious financial trouble, and a 2027 maturity was not far away. The company launched an exchange offer, inviting holders of those notes to swap them for a new package of securities.
What noteholders received in exchange was a combination of three things. First, up to $72.0 million in new 7.50% Convertible Senior Secured First Lien Notes due 2030. Second, up to 317,647,058 shares of common stock or pre-funded warrants (which function similarly to shares). Third, holders who tendered before the extended early deadline of June 2, 2026 received additional purchase warrants on top of everything else. The early settlement for those early tenderers occurred on June 4, 2026.
By the final deadline of June 16, 2026, holders representing $181,052,000 of the original notes had tendered, which came to roughly 90.5% of the total outstanding. That met the amended minimum participation threshold the company set during the offer process. The remaining $18,948,000 in original notes was not tendered and will stay outstanding under the old terms.
The structural shift here is meaningful. The old notes were unsecured, meaning if Gossamer ever faced a liquidation scenario, those noteholders would stand behind secured creditors in the repayment line. The new notes carry a first lien, secured position, which places those holders at the front of the line. The maturity also moved from 2027 to 2030, giving the company three additional years before the debt comes due. The interest rate on the new notes is higher at 7.50% versus the original 5.00%, which reflects the company’s risk profile and current market conditions.
The share issuance is where the numbers become striking. Gossamer had approximately 234.7 million shares outstanding before this transaction. The exchange offer introduces up to 317,647,058 new shares, which is about 35% more than the entire existing share count. The total share count, once fully settled, could exceed 550 million shares, depending on how pre-funded warrants are exercised. That is a significant expansion of the share base, and existing shareholders now own a proportionally smaller piece of the company.
The reason the company took this path is straightforward. Gossamer’s lead drug candidate, seralutinib, is an inhaled therapy targeting the cellular and vascular changes that drive PAH. The company is developing it in partnership with the Chiesi Group, a privately held Italian pharmaceutical company. Gossamer is targeting an NDA submission to the FDA in September 2026, with a potential FDA decision as early as the third quarter of 2027. Getting to that decision point requires time and cash, and extending the debt maturity to 2030 provides a clearer financial runway to reach it
The exchange offer reflects a company making calculated trade-offs to keep its pipeline funded and its debt obligations manageable. The dilution is real and quantifiable. Whether it turns out to matter depends on what happens with seralutinib over the next 12 to 18 months. The new first lien notes represent a shift in who stands at the front of the line if things go wrong, and the extended 2030 maturity represents the company’s bet that things will go right.
